CYCC_OUT_1 [2025-04-25 12:18:02 -0400] 5837 Bytes | 1503 tokens | Cum: 1503 tkns (18.79% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 12:18 PM on Fri Apr 25, 2025, and I'm firing up the spotlight on Cyclacel Pharmaceuticals (CYCC), moving from $0.2290 to $0.2778. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Cyclacel Pharmaceuticals (CYCC)
IPO: 2006-03-28 (19 Years Ago)
Market Cap: $46,878,758
Shares Outstanding: 207,340,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

Here’s a list of headlines for Cyclacel Pharmaceuticals:

Apr-02-25 04:05PM - Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
Mar-24-25 07:30AM - Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
Feb-27-25 01:38PM - Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
Jan-03-25 09:01AM - Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Dec-05-24 04:05PM - Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Nov-14-24 04:15PM - Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Nov-13-24 12:22PM - Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Nov-12-24 06:00PM - Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
Nov-12-24 06:00PM 04:45PM - Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Oct-24-24 09:15AM - Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
Oct-23-24 09:15AM - Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Oct-09-24 09:15AM - Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Sep-25-24 09:15AM - Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Sep-04-24 09:15AM - Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Sep-03-24 09:15AM - Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Sep-02-24 09:55AM - Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aug-14-24 05:35PM - Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
Aug-14-24 05:35PM 04:05PM - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
Aug-07-24 09:15AM - Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
Jul-25-24 12:00PM - Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
Jun-26-24 09:15AM - Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Jun-06-24 12:00PM - All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-27T18:38:00Z - Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
B2 - 2024-09-03T17:52:14Z - Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
B3 - 2024-06-26T13:15:00Z - Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
B4 - 2024-06-06T16:00:10Z - All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
B5 - 2024-05-08T13:15:00Z - Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
B6 - 2024-05-02T20:30:00Z - Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Cyclacel Pharmaceuticals (CYCC).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CYCC_OUT_3 [2025-04-25 12:18:03 -0400] 867 Bytes | 221 tokens | Cum: 1726 tkns (21.57% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/27/3034209/10564/en/Cyclacel-Pharmaceuticals-Announces-Closing-of-a-Change-of-Control-Transaction-and-Appointment-of-New-Executive-Leadership.htmlCyclacel Pharmaceuticals announced a change in control and leadership, with Datuk Dr. Doris Wong Sing Ee becoming the new CEO and Kiu Cu Seng appointed as Executive Director, Secretary and Chief Financial Officer.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_5 [2025-04-25 12:18:04 -0400] 991 Bytes | 262 tokens | Cum: 1990 tkns (24.88% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T20:05:00Z - Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update...
A2 - 2025-04-02T20:20:03Z - Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update...
A3 - 2025-04-02T20:20:40Z - Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update | Tai...
A4 - 2025-03-31T16:18:06Z - CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com...
A5 - 2025-03-31T16:20:05Z - CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CYCC_OUT_7 [2025-04-25 12:18:05 -0400] 1182 Bytes | 319 tokens | Cum: 2311 tkns (28.89% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update**Date: 2025-04-02Source: {'uri': 'forextv.com', 'dataType': 'news', 'title': 'ForexTV'}URL: https://forextv.com/cyclacel-pharmaceuticals-reports-fourth-quarter-financial-results-and-provides-business-update/BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.

"As part of Cyclacel's efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies, which we acquired on March 10, 2025, from Cyclacel Limited, our wholly-own

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_9 [2025-04-25 12:18:06 -0400] 1182 Bytes | 278 tokens | Cum: 2591 tkns (32.39% of 8k)
==========================================================================

Showing A1 (chunk 2 of 11): ed subsidiary that is currently in liquidation," said Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director. "Our new, alternative salt, oral formulation of plogosertib with improved bioavailability is under development."

"The commencement of the liquidation of Cyclacel Limited means that the Company will no longer have control over Cyclacel Limited and its financial results will be deconsolidated from those of the Company; as a result, the Company anticipates a significant decrease to research and development expenses for the year ended December 31, 2025 as we focus on our plogosertib clinical program and have no expenditures related to fadraciclib," said Kiu Cu Seng, Chief Financial Officer. "The deconsolidation of Cyclacel Limited, which is anticipated to increase stockholders' equity by approximately $5.0 million, will be reported in the Company's Form 10-Q fo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_11 [2025-04-25 12:18:06 -0400] 1182 Bytes | 313 tokens | Cum: 2906 tkns (36.33% of 8k)
==========================================================================

Showing A1 (chunk 3 of 11): r the three months ended March 31, 2025."

Financial Highlights

As of December 31, 2024, pro forma cash and cash equivalents totaled $7.2 million, including $4.1 million of equity financing received after the end of the year. Cash and cash equivalents as of December 31, 2024, totaled $3.1 million, compared to $3.4 million as of December 31, 2023. Net cash used in operating activities was $8.0 million for the twelve months ended December 31, 2024 compared to $16.1 million for the same period of 2023. The Company estimates that its available cash, including the equity financing of $4.1 million, will fund currently planned activities into the second quarter of 2025.

Research and development (R&D) expenses were $0.9 million and $6.7 million for the three months and year ended December 31, 2024, as compared to $3.5 million and $19.2 million for the same period in 2023. R&D expenses relating

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_13 [2025-04-25 12:18:07 -0400] 1182 Bytes | 316 tokens | Cum: 3224 tkns (40.30% of 8k)
==========================================================================

Showing A1 (chunk 4 of 11): to fadraciclib were $0.8 million and $5.0 million for the three months and year ended December 31, 2024, as compared to $2.7 million and $13.4 million for the same period in 2023 due to decrease in clinical trial and other non-clinical expenditures. R&D expenses related to plogosertib were $0.1 million and $1.6 million for the three months and year ended December 31, 2024, as compared to $0.7 million and $5.0 million for the same period in 2023 due to decrease in clinical trial and other non-clinical expenditures.

General and administrative expenses for the three months and year ended December 31, 2024, were $0.9 million and $5.4 million, compared to $1.9 million and $6.7 million for the same period of the previous year due to a decrease in stock compensation and professional and corporate fees.

Total other income, net, for the three months and year ended December 31, 2024, were an ex

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_15 [2025-04-25 12:18:08 -0400] 1182 Bytes | 303 tokens | Cum: 3529 tkns (44.11% of 8k)
==========================================================================

Showing A1 (chunk 5 of 11): pense of $30,000 and income of $10,000, compared to an expense of $333,000 and $98,000 for the same period of the previous year, due to foreign exchange movements.

United Kingdom research & development tax credits for the three months and year ended December 31, 2024 were a debit of $1.2 million and a credit of 0.8 million compared to credits $0.4 million and $3.0 million for the same period of the previous year and are directly correlated to qualifying research and development expenditure.

Net loss for the three months and year ended December 31, 2024, was $3.0 million and $11.2 million (including stock based compensation expense of $0.1 million and $0.6 million respectively), compared to $5.3 million and $22.6 million (including stock based compensation expense of $0.3 million and $1.5 million respectively) for the same period in 2023.

Board and Committee Appointments

On April 2, 2

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_17 [2025-04-25 12:18:08 -0400] 1182 Bytes | 292 tokens | Cum: 3823 tkns (47.79% of 8k)
==========================================================================

Showing A1 (chunk 6 of 11): 025, coinciding with the effective time of the previously announced resignations of Avraham Ben-Tzvi and David Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company's board of directors (the "Board") to fill the vacancies.

Dr. Satis Waran Nair Krishnan (age 39) is a Medical Doctor at Centric Health in Drogheda, County Louth, Ireland. Dr. Krishnan is a highly experienced practitioner originally from Malaysia. Dr. Krishnan joined Centric Health in Ireland September 2023. Prior to that, from 2010 to August 2023, Dr. Krishnan was a Doctor in the public health field for the Ministry of Health Malaysia, With a decade of practice in Malaysia and training in Dermatology from the Association of Family Physicians of Malaysia (AFPM) and the Institute of Dermatology in Bangkok, Thailand, Dr. Krish

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_19 [2025-04-25 12:18:09 -0400] 1182 Bytes | 284 tokens | Cum: 4109 tkns (51.36% of 8k)
==========================================================================

Showing A1 (chunk 7 of 11): nan brings a wealth of expertise to our team. Dr. Nair is proficient in English, Russian and Ukrainian, he is dedicated to providing patient-centered care and promoting overall well-being. Dr. Krishnan received his medical degree in 2010 and Professional Diploma of General Dermatology in 2023.

Inigo Angel Laurduraj (age 40) brings extensive audit and accounting services to the Company over her 20 years in that industry. Ms. Laurduraj served as a Senior Accounting Manager at IOI Oleochemicals Sdn. Bhd., an edible oil refining and Oleochemicals company for 11 years from 2007 through 2018. Prior to that, she served from 2005 through 2005 as an Auditor for Moore Stephens (now Moore Global), a global firm operating in 114 countries specializing in accounting and finance services, audit and assurance, fund services, private client services, corporate services, and tax services. Ms. Laurduraj

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_21 [2025-04-25 12:18:10 -0400] 1182 Bytes | 286 tokens | Cum: 4397 tkns (54.96% of 8k)
==========================================================================

Showing A1 (chunk 8 of 11): earned an Association of Chartered Certified Accountants (ACCA) in 2015 and a Bachelors of Arts in Accounting in 2014.

In connection with Ms. Laurduraj and Dr. Krishnan's appointment, as well as the Board's recent appointment of Mr. Kwang Fock Chong as independent director, on April 2, 2025, the Board also approved the following committee appointments:

The Company wishes to express its gratitude to the departing directors for their dedicated service and their support of Cyclacel's efforts to serve the unmet medical needs of cancer patients.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. The epigenetic/anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's stra

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_23 [2025-04-25 12:19:14 -0400] 1182 Bytes | 239 tokens | Cum: 4638 tkns (57.98% of 8k)
==========================================================================

Showing A1 (chunk 9 of 11): tegy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, Cyclacel's future plans and prospects, Cyclacel's anticipated cash runway and the planned timing of data results and continued development of plogosertib. Factors that may cause actual results to differ materially include market and other conditions, the risk that product candidates that appeared promising in early research and clin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_25 [2025-04-25 12:19:14 -0400] 1183 Bytes | 265 tokens | Cum: 4905 tkns (61.31% of 8k)
==========================================================================

Showing A1 (chunk 10 of 11): ical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates and Cyclacel's ability to regain and maintain compliance with Nasdaq's continued listing requirements, although no assurance to that effect can be given. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncert

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_27 [2025-04-25 12:19:15 -0400] 1073 Bytes | 272 tokens | Cum: 5179 tkns (64.74% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-02 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

Cautionary Statement Regarding Forward-Looking Stmnts

This report contains certain statements that may be deemed forward-looking statements within the meaning of United States se...

S2 - 2025-04-02 8-K Item 2.02 Results of Oper and Fin Cond.

The information set forth under this Item 2.02. Results of Oper and Fin Cond, including the exhibit attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of ...

S3 - 2025-03-24 8-K I tem 1.01 Entry into a Material Definitive Agrmt.

Securities Purchase Agrmt

On March 21, 2025, Cyclacel Pharmaceuticals, Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with certain accredited investors (the Investors), pursua...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CYCC_OUT_29 [2025-04-25 12:19:16 -0400] 1181 Bytes | 234 tokens | Cum: 5415 tkns (67.69% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statement Regarding Forward-Looking Statements

This report contains certain statements that may be deemed forward-looking statements within the meaning of United States securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Certain factors that could cause results to differ materially from those projected or implied in the forward-looking

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_31 [2025-04-25 12:19:17 -0400] 1181 Bytes | 262 tokens | Cum: 5679 tkns (70.99% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): statements are set forth in this Annual Report on Form 10-K for the year ended December 31, 2024 under the caption Item 1A Risk factors.

We encourage you to read those descriptions carefully. We caution you not to place undue reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law. Such forward-looking statements are not guarantees of future performance and actual results will likely differ, perhaps materially, from those suggested by such forward-looking statements.

We effected a 15:1 reverse stock split of our common stock on December 18, 2023 (the Reverse Stock Split). All share and per share information has been retroactively adjusted to give eff

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_33 [2025-04-25 12:19:17 -0400] 1181 Bytes | 259 tokens | Cum: 5940 tkns (74.25% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ect to the Reverse Stock Split for all periods presented, unless otherwise indicated.

Recent developments

In December 2024 the Company announced that it was in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Companys cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, or Lazar. The Companys Board of Directors (the Board) reviewed a range of appropriate strategies to realize value from its assets. The Board directed management to reduce operating costs, which included the potential liquidation of the Companys wholly owned United Kingdom subsidiary Cyclacel Limited, or Subsidiary, while such alternatives were being explored. On January 2, 2025 the Company entered into a securities purchase agreement with investor Lazar, pursuant to which he agreed to purchase from the Company 1,000,00

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_35 [2025-04-25 12:19:18 -0400] 1181 Bytes | 276 tokens | Cum: 6218 tkns (77.72% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): 0 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel at a purchase price of $1.00 per share for aggregate gross proceeds of $3.1 million, subject to the terms and conditions of the Agreement. The proceeds of the transaction will be used to settle outstanding liabilities of the Company and other general corporate and operating purposes.

On January 2, 2025 the Company entered into a securities purchase agreement with investor Lazar, pursuant to which he agreed to purchase from the Company 1,000,000 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel at a purchase price of $1.00 per share for aggregate gross proceeds of $3.1 million, subject to the terms and conditions of the Agreement. The proceeds of the transaction will be used to settle outstanding l

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_37 [2025-04-25 12:19:19 -0400] 1181 Bytes | 273 tokens | Cum: 6493 tkns (81.16% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): iabilities of the Company and other general corporate and operating purposes.

On January 2, 2025, the Company entered into settlement agreements with the Resigning Directors effective as of the signing of the Purchase Agreement. Pursuant to the terms of the Director Settlement Agreements, each Resigning Director resigned his or her position as a member of the Board of Directors, and any positions held on committees of the Board of Directors. Each Resigning Director has received his or her accrued Board fees in full consideration of the release of claims against the Company and other promises and covenants set forth in the Director Settlement Agreements.

On January 2, 2025, the Company entered into a settlement agreement with Mr. Spiro Rombotis (the Rombotis Settlement Agreement). Pursuant to the terms of the Rombotis Settlement Agreement, Mr. Rombotis resigned his position as Preside

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_39 [2025-04-25 12:19:19 -0400] 790 Bytes | 194 tokens | Cum: 6689 tkns (83.61% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): nt and Chief Executive Officer of the Company effective as of the signing of the Purchase Agreement, and agreed to provide transition services to the Company in his capacity as a member of the Board of Directors through

the filing of the Companys Annual Report on Form 10-K for the year ended 2024. On January 2, 2025, the Company also entered into a settlement agreement with Paul McBarron (together with Mr. Rombotis, the Resigning Officers) effective immediately following the Initial Closing, as su...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CYCC_OUT_41 [2025-04-25 12:19:26 -0400] 6779 Bytes | 1807 tokens | Cum: 8498 tkns (106.22% of 8k)
==========================================================================

This is our set of metrics for Cyclacel Pharmaceuticals.
Please analyze the numbers.

+---------------------+------------------------+------------------------+------------------------+
| Volume: 2,487,160 | Perf Month: -10.68% | Option/Short: No / Yes | Sales Y/Y TTM: -89.76% |
+---------------------+------------------------+------------------------+------------------------+
| Avg Volume: 290.75K | Perf Quarter: -26.71% | Short Float: 0.44% | ROE: -807.39% |
+---------------------+------------------------+------------------------+------------------------+
| Rel Volume: 20.35 | Index: - | Short Ratio: 0.19 | ROI: - |
+---------------------+------------------------+------------------------+------------------------+
| RSI (14): 55.50 | Market Cap: 56.37M | Short Interest: 0.06M | Sales Surprise: - |
+---------------------+------------------------+------------------------+------------------------+
| ATR (14): 0.03 | Shs Outstand: 207.34M | Beta: 0.56 | EPS Surprise: - |
+---------------------+------------------------+------------------------+------------------------+
| SMA20: 15.99% | Shs Float: 12.71M | Sales Q/Q: -100.00% | P/E: - |
+---------------------+------------------------+------------------------+------------------------+
| SMA50: -5.43% | Inst Own: 0.34% | Sales past 5Y: -17.95% | Earnings: Apr 02 AMC |
+---------------------+------------------------+------------------------+------------------------+
| SMA200: -60.54% | Insider Own: 93.87% | Employees: - | |
+---------------------+------------------------+------------------------+------------------------+
| Perf Week: 20.26% | Insider Trans: -50.00% | Debt/Eq: - | |
+---------------------+------------------------+------------------------+------------------------+

The next section covers any insider trading by Cyclacel Pharmaceuticals officers or majority shareholders (if available).

Inside Trans: Cyclacel Pharmaceuticals, Inc. (CYCC) by Ben-Tzvi Avraham (Unknown Title) on 2025-02-26
- Non-Qualified Stock Option (Right to Buy): 700000 shares at $0 (D)

Inside Trans: Cyclacel Pharmaceuticals, Inc. (CYCC) by Lazar David E. (Interim CEO) on 2025-02-26
- Common Stock: 2650000 shares at $N/A (D)
- Common Stock: 191978820 shares at $N/A (D)
- Common Stock: 194628820 shares at $0.0283 (D)
- Series C Convertible Preferred Stock: 1000000 shares at $N/A (D)
- Series D Convertible Preferred Stock: 1745262 shares at $N/A (D)

Inside Trans: Cyclacel Pharmaceuticals, Inc. (CYCC) by NATAN DAVID (Unknown Title) on 2025-02-26
- Non-Qualified Stock Option (Right to Buy): 700000 shares at $0 (D)

No transactions recorded.

No transactions recorded.

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 74000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -13476000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.278899
Average Volume: 299584.73
30-Day High: 0.3058
30-Day Low: 0.188

[Detailed Financials: Q3 2024]
- Total Assets: $5,381,000.00
- Total Liabilities: $6,351,000.00
- Total Equity: $-970,000.00
- Current Assets: $4,913,000.00
- Current Liabilities: $6,351,000.00

[Income Statement: Q3 2024]
- Revenue: $10,000.00
- Net Income: $-1,957,000.00
- Gross Profit: N/A
- Operating Income: $-2,177,000.00
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0.00

[Detailed Financials: Q2 2024]
- Total Assets: $8,190,000.00
- Total Liabilities: $7,191,000.00
- Total Equity: $999,000.00
- Current Assets: $7,707,000.00
- Current Liabilities: $7,186,000.00

[Income Statement: Q2 2024]
- Revenue: $4,000.00
- Net Income: $-3,257,000.00
- Gross Profit: N/A
- Operating Income: $-3,644,000.00
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Cyclacel Pharmaceuticals (CYCC).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Cyclacel Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because CYCC is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CYCC.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CYCC could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CYCC to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Cyclacel Pharmaceuticals.

11) ETHICAL_RATING[]
Rate Cyclacel Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Cyclacel Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CYCC_IN_43 [2025-04-25 12:19:27 -0400] 126 Bytes | 29 tokens | Cum: 8719 tkns (108.99% of 8k)
==========================================================================

====================================
[2025-04-25 12:19:27] # Analysis Completed
Elapsed Time: 84.99 seconds